Royalty Report: Drugs, Delivery, Pain – Collection: 289191

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Delivery
  • Pain
  • Cancer
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 289191

License Grant
Licensor grants the Licensee of China an exclusive license, without rights of sublicense, in the Field
under the Licensed Technology to market, advertise, promote, distribute for commercial sale, offer
for sale, sell, and import for commercial sale the Licensed Product in the Territory and Licensor
hereby grants a non-exclusive license, without rights of sublicense, under the Licensed Technology to develop in the Territory the Licensed Product for additional human therapeutic indications following Governmental Approval of such Licensed Product in the Territory for the Initial Indication.
License Property
Licensed Product means the 200mcg, 400mcg, 600mcg, 800mcg, and 1200mcg dosage strengths of that BEMA-based product which contains fentanyl as its sole API, is the subject of MAA DCP DE-H-1660-001-006-DC and NDA 022266 and, is supplied to Licensee by Licensor.

Product means the Licensed Product, Placebos, and Demonstration Samples.

The Drug Product is BEMA rM Fentanyl, Bucco/ Soluble Film

BEMA means the proprietary bioerodible, mucoadhesive multi-layer polymer film technology Controlled by Licensor.

Field of Use
A Competing Product means a pharmaceutical product that is labeled or marketed for the indication of breakthrough pain and incorporates fentanyl as an API.

The Field means the treatment of breakthrough cancer pain in patients tolerant to opioids, the Initial Indication, and, following Governmental Approval in the Territory of the Licensed Product for the Initial Indication, any additional human therapeutic indications for which Governmental Approval is obtained.

IPSCIO Record ID: 256300

License Grant
The Licensor of Germany grants a non-exclusive, non-transferable, license to and under the patent to make, have made, use, have used, offer to sell, sell, have sold or import or have imported the Product.

The Parties wish to cooperate in the exclusive manufacturing of the Products and Placebos in the Territory.

License Property
The licensed property is EP O 949 925.

The Active Principle shall mean Fentanyl.

The Product shall mean Licensees transmucosal oral system containing Active Principle based on the Design of Licensee Technology.  

Licensee has bioerodable mucoadhesive transmucosal technology.

Licensor has technology and process for oral film form products and/or pharmaceutical preparations in general, their use, process development, including without limitation the mass preparation, coating, drying and compiling thereof, and, manufacturing, packaging, and labeling.

U.S. Patents Nos. 5,948,430, 6,177,096 and 6,284,264

Field of Use
Both Parties have experience with the oral film-form products industry.

The Licensee lead BEMAâ„¢ product under development is BEMAâ„¢ Fentanyl, a treatment for breakthrough cancer pain.

IPSCIO Record ID: 212269

License Grant
The Company is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Licensee.  The Company secured a new commercial partner for ONSOLIS® when a licensing agreement was completed.
License Property
ONSOLIS® a buprenorphine depot product for treatment of opioid dependence in the field of microencapsulation-based controlled/sustained release and drug delivery technologies.
Field of Use
Onsolis (fentanyl buccal soluble film) is an opioid analgesic indicated for the management of breakthrough pain in cancer.

Licensee will be responsible for the manufacturing, distribution, marketing and sales of ONSOLIS in the U.S.

IPSCIO Record ID: 4069

License Grant
In connection with the Licensor's consent to our U.S. licensing transaction with Meda AB relating to ONSOLISâ„¢, we and the Licensor entered into a second Dispute Resolution Agreement pursuant to which we and the Licensor agreed to waive and dismiss with prejudice all current disputes between us, concerning each of the Clinical Development and Licensing Agreements and a securities purchase Agreement that we previously entered into which disputes had commenced during 2006.
License Property
BEMAâ„¢ (BioErodible MucoAdhesive) drug delivery system

The BEMA® drug delivery technology is a buccal soluble film consisting of a small, BioErodible polymer film for application to the mucosal membranes (inner lining of cheek). BEMA® films were designed to rapidly deliver a dose of drug across the mucous membranes for time sensitive conditions.

Field of Use
The rights apply to the healthcare industry.

IPSCIO Record ID: 282856

License Grant
Licensor hereby grants to Licensee, subsidiary, a sole and exclusive, royalty-bearing license under the BEMA Technology to use, develop, market, advertise, promote, distribute, offer for sale, sell, export and import, manufacture, and have manufactured Products in the Territory, with the right to sublicense in accordance with this agreement. Subject to the terms of this Agreement, Licensee shall have the right to assign this Agreement, on the basis set forth in this agreement. During the term of this Agreement, Licensor shall not grant any right or license to any third party with respect to the BEMA Technology in the Territory.

Licensor hereby grants to Licensee a sole and exclusive, royalty-free license to use the Marks solely in connection with the use, promotion, marketing, distribution, offer for sale, and sale of the Products, on a Product-by-Product basis, in the Territory during the Royalty Term. Licensee may grant a sublicense to the Marks in accordance with this agreement.

License Property
BEMA means Licensor’s proprietary bioerodible, mucoadhesive multi-layer polymer film.

Marks means “BEMA” or any additional trademarks owned by Licensor with respect to the BEMA Technology, alone or accompanied by any logo or design and any non-English language equivalents in figure, sound or meaning, whether registered or not.

Product means individually and collectively any product which, but for the licenses granted under this Agreement, would infringe one or more valid claims of the BEMA Patent Rights.

Fentanyl Product means the first Product containing Fentanyl, used for the treatment of pain and sold in a Commercial Sale.

BEMA Patent Rights means all Patent Rights in the Territory related to the patents and patent applications listed, claiming BEMA or any Improvement, or which are necessary or appropriate to develop, manufacture and commercialize Products in the Territory, and that are under the Control of Licensor as of the Effective Date or that come under Licensors Control during the Term.
5,800,832 – Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
6,159,498 – Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces

BEMA Technology means the BEMA Patent Rights and the BEMA Know How.

Patent Rights means all rights under patents and patent applications, and any and all patents issuing therefrom (including utility, model and design patents and certificates of invention), together with any and all substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues, divisionals, continuations, continuations-in-part, re-examinations, renewals and foreign counterparts of the foregoing, and all improvements, supplements, modifications or additions.

Field of Use
BEMA(TM) is an acronym for “Bioerodible Mucoadhesive”, and consists of a patented oral BEMA™ disc, which delivers the drug through the mucosal surface (inner cheek) by placing the disc between the cheek and gum.

The BEMA(TM) technology allows for the delivery of drugs across the buccal (i.e., mouth) mucosa that provides a rapid onset of therapeutic effect and a competitive advantage in such areas as pain relief and sedation.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.